4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $753,662.36 in Stock

Key Points

• Insider sale: David Kirn sold 58,333 FDMT shares for $753,662 at an average price of $12.92, reducing his direct ownership by 7.6% to 709,153 shares.
• Stock and financial performance: FDMT recently traded at $12.59, while the company reported a quarterly loss of $1.04 per share—slightly worse than estimates—and $3.78 million in revenue.
• Analyst and institutional sentiment: Analysts maintain a “Moderate Buy” consensus with an average price target of $28.90, and institutional investors own 99.27% of the company’s shares.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider David Kirn sold 58,333 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $12.92, for a total value of $753,662.36. Following the sale, the insider directly owned 709,153 shares in the company, valued at approximately $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

David Kirn also recently made the following trade(s):

• On Monday, September 14th, David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.90, for a total value of $810,828.70.
• On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.05, for a total value of $124,770.75.
• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.03, for a total value of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.87, for a total value of $548,364.96.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock traded up $0.03 on Wednesday, hitting $12.59. 603,567 shares of the company's stock were exchanged, compared to its average volume of 855,943. The company has a 50 day moving average of $13.61 and a 200 day moving average of $11.34. The stock has a market cap of $695.47 million, a P/E ratio of -4.79 and a beta of 2.75. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. 4D Molecular Therapeutics, Inc. has a 12 month low of $6.96 and a 12 month high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. On average, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on FDMT. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group reaffirmed a "buy" rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 price target for the company in a report on Monday, September 14th. Chardan Capital dropped their price target on 4D Molecular Therapeutics from $26.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, B. Riley Financial reissued a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $28.90.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC acquired a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $76,466,000. BlackRock Inc. acquired a new position in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $60,463,000. Janus Henderson Group PLC increased its position in 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock valued at $48,868,000 after acquiring an additional 611,276 shares during the period. Trails Edge Capital Partners LP bought a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $29,631,296. Finally, Bank of America Corp DE bought a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $14,905,000. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.